Impact of psychostimulants on vesicular monoamine transporter function.
about
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)Toxicity of amphetamines: an updateVesicular monoamine transporter 2: role as a novel target for drug developmentDefunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporterDysfunctional play and dopamine physiology in the Fischer 344 rat.Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.A tyrosine-based motif localizes a Drosophila vesicular transporter to synaptic vesicles in vivo.Mice lacking multidrug resistance protein 1a show altered dopaminergic responses to methylenedioxymethamphetamine (MDMA) in striatumSynergism between methamphetamine and the neuropeptide substance P on the production of nitric oxide in the striatum of miceContrasting Effects of the Neuropeptides Substance P, Somatostatin, and Neuropeptide Y on the Methamphetamine-Induced Production of Striatal Nitric Oxide in Mice.Mechanisms of methamphetamine-induced dopaminergic neurotoxicity.Methamphetamine-induced dopamine terminal deficits in the nucleus accumbens are exacerbated by reward-associated cues and attenuated by CB1 receptor antagonism.Effects of D2 or combined D1/D2 receptor antagonism on the methamphetamine-induced one-trial and multi-trial behavioral sensitization of preweanling ratsEvidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology.On the effects of psychostimulants, antidepressants, and the antiparkinsonian drug levodopa on dopamine neurons.Early ontogeny of D-amphetamine-induced one-trial behavioral sensitizationThe role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits.Differential regional effects of methamphetamine on dopamine transport.Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2Cocaine, metamfetamine, and MDMA abuse: the role and clinical importance of neuroadaptation.Vesicular and plasma membrane transporters for neurotransmitters.VMAT2 and dopamine neuron loss in a primate model of Parkinson's diseasePositron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.Sex differences in K+-evoked striatal dopamine output from superfused striatal tissue fragments of reserpine-treated CD-1 mice.Evaluating Exercise as a Therapeutic Intervention for Methamphetamine Addiction-Like Behavior.Neuropharmacology of Attention-Deficit/Hyperactivity Disorder
P2860
Q22251113-E556F138-7B9C-4FE7-99B8-F2FFB150E91EQ22252794-36CE70A3-D338-4A9B-A67E-1F1652849B8FQ24647764-DE120061-516F-4932-9935-96D610CF96A9Q28267727-66DBD2F9-8DB3-485B-A98F-C0B6DFC411B3Q30465894-487119FE-861C-4A3A-87C1-417DABC2E27CQ30512976-759C7095-8F1E-40C7-8B4C-E80A115603DDQ33738102-63B94831-FB02-46EB-BCD4-A92EB377DB27Q33747909-8F477181-C5AE-4AD9-8674-0C13A18CBD24Q34051713-52BDDE74-25FB-49C1-B891-35EE1BDAB4D9Q34459294-5B2C37CC-F85F-4A4B-970D-9EF71AFC5F35Q34470931-4F003A33-0005-42EC-93B3-DE6E19015027Q35594901-520F73EA-4D30-489D-858B-DD260CA0A359Q36457393-98A84525-C175-4023-BAC7-F9B03F1FBBEFQ36578099-E095BA4F-6FF2-4812-95FD-946C1A844FF0Q36648476-E6B93A39-4E49-421A-A69E-91E8A250BA81Q36653973-8A680CD7-CE08-4138-A8AF-0419AC8EF3BDQ36675304-FD34C7E9-9AE4-41E0-BD29-34BD05F34B0FQ36717509-74BB0FF6-6782-4126-9CE8-D2030BAEC8E7Q36968822-7CDC9304-8197-416B-A5EE-62D1425534C0Q36968827-81AC80E5-F8EA-4454-A4FF-5DA4711A28BDQ37789757-51686378-30EA-4563-9546-CBADE89E92C3Q37971367-6BBE740B-FE6D-4EAE-A0D7-903C5E73B951Q42239029-120CB1ED-E5F8-4490-A955-7D7D8386BF4CQ46900351-CA98F71F-B875-42DD-9A66-D0894DE1199AQ51743205-F844B6D2-783E-4530-95F9-BDC68E646840Q55286284-79931784-2461-4109-9DEB-66AF2FC1038FQ57277979-51CBDC7B-9DE0-4E80-BCF6-B5AD4E47C3DA
P2860
Impact of psychostimulants on vesicular monoamine transporter function.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Impact of psychostimulants on vesicular monoamine transporter function.
@ast
Impact of psychostimulants on vesicular monoamine transporter function.
@en
type
label
Impact of psychostimulants on vesicular monoamine transporter function.
@ast
Impact of psychostimulants on vesicular monoamine transporter function.
@en
prefLabel
Impact of psychostimulants on vesicular monoamine transporter function.
@ast
Impact of psychostimulants on vesicular monoamine transporter function.
@en
P1476
Impact of psychostimulants on vesicular monoamine transporter function.
@en
P2093
Annette E Fleckenstein
Glen R Hanson
P304
P356
10.1016/J.EJPHAR.2003.08.077
P407
P577
2003-10-01T00:00:00Z